MSK thoracic oncologist Dr. Alissa Cooper shares research on #neuroendocrine tumors at #ASCO25.

Phase 3 trial showed Tarlatamab is superior in efficacy and safety than chemotherapy in SCLC 2nd line setting, first OS benefit since topotecan for the past 30 years. Subgroup analyses showed those with brain Mets had even more benefit (HR 0.57). Congrats to all investigators!

🚨 U.S. FDA approves taletrectinib for ROS1+ mNSCLC Treatment-naïve: ▫️ORR: 90% (TRUST-I), 85% (TRUST-II) ▫️DOR ≥12 mo: 72%, 63% TKI-pretreated: ▫️ORR: 52% (TRUST-I), 62% (TRUST-II) ▫️DOR ≥6 mo: 74%, 83% ⚠️ liver tox, ILD/pneumonitis, QTc, hyperuricemia, myalgia, fractures

🎉🎉🎉We celebrate #FDA approval of #zongertinib as the first TKI in #HER2-mutant #NSCLC 🎊 🎂 🌺 🩷 👉 ORR 71% 👉 Duration of Response 14.1 months 👉 PFS 12.4 months 👉 Well-tolerated at 120mg dose 📖 In previously treated patients without prior anti-HER2 targeted therapies

KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer dlvr.it/TMVKGH

Important paper put out by stellar MDA colleagues! Congrats to all co- authors. Lauren Averett Byers, MD Natalie Vokes John Heymach MD Anderson Cancer Center

Compelling data from phase 1 trial of rhenium obisbemeda for LMD. With single administration: -mOS 9 months -13/16 pts with reduction in CSF CTCs Multi dose study now enrolling! Clinicaltrials.gov: NCT07098806 SNO

⭐️This year has already seen MAJOR advances in #lungcancer therapies, especially for #EGFR #NSCLC, #SCLC, & the neoadjuvant space. 👇🏾With #WCLC25 around the corner, this is my personal list of the MOST EXCITING abstracts to be showcased this year & why I think they are great!

Not all dogs are the same - and not all SCLC are the same. Join us on Saturday morning Sept 6 @ WS02.01 - New Insights into SCLC Biology and Subtypes. IASLC SmallCellSMASHERS LUNGevity Foundation Lung Cancer Research Foundation BostonGeneCorp. Anne Chiang Ignacio Wistuba, MD #WCLC25 #SCLC

Great introduction to the subtypes and potential sensitivity to therapeutic types. It’s interesting which proteins are over expressed on each subtype preferentially and how the commercial reports will provide room for the plasticity of disease.

Wow! What a turnout - thanks to our great panelists and for all of you who joined. This is a turning point for #SCLC new therapeutics + SCLC Subtypes - and just the tip of the iceberg. At the next WCLC, I predict we will need even a bigger room. (View feom the podium…)

Exciting new data in the era of ADCs for tx SCLC. Great news for patients to have early access to these novel therapies. We need more translational studies for predictive biomarkers to inform treatment selection, sequencing and combinatorial studies. #WCLC25 Lauren Averett Byers, MD

Rock star Eric K. Singhi, MD with a great message for patients and advocates on leveraging social media to improve their cancer outcomes, experience, and support community. Incredible messages. Thanks for all you do for patients! #WCLC25

The encouraging and evolving landscape of 1st line treatment of ES-SCLC! Phase 3 DeLLphi-303 showed OS of over 25 months with maintenance tarlatamab plus PD-L1. Pumitamig (VEGF/PDL1 bispecific) showed encouraging ORR, and raddiologand therapy entering the 1st line space also.

How do we improve long term survival in patients with ES-SCLC? Excellent discussions and insights from Dr. Charlie Rudin.

🔥🚨OncoAlert HOT OFF THE PRESS. Just published The Lancet Oncology In conjunction with presentation IASLC #WCLC25 Impressive Results of: ⭐️#DeLLphi303: Phase 1b trial of: #Tarlatamab + anti-PD-L1 as #maintenance Tx after 1st line Chemo/IO in ES #SmallCell #LungCancer